Professor Karla Zadnik, Dean of the Ohio State University College of Optometry in the USA,, discusses the Childhood Atropine for Myopia Progression (CHAMP) study, engaging with the literature, her favourite papers and an alternative take on myopia control as standard of care.
The research information on using atropine for myopia control is evolving. Previous research indicated 0.01% atropine was best, but newer research says otherwise. In this clinical case, practitioners discuss treatment strategies, which are put in research context with clinical pearls for practice.
A child has an allergic reaction to low dose atropine – or does he? Here practitioners consider the possible causes, with advice for management. We then frame this discussion in view of the evidence-base with take home clinical messages.
Atropine can be used for myopia control as a monotherapy or as an adjunct to an optical intervention – we discuss patient selection, atropine combination treatments, how to taper and when to stop.
Read these three clinical complex atropine cases where general health conditions required careful consideration of atropine prescribing for myopia control.
Most atropine currently prescribed for myopia control is compounded. How could this influence consistency of treatment and research results? What could current research lead to in future prescribing? Read more here.
As there are systemic side effects of atropine eye drops, they could be contraindicated in young patients with some conditions, syndromes, and when taking specific systemic medications. Medication safety is also discussed.
The atropine landscape is constantly evolving as new studies are published. Here is a compiled summary of all of the most recent atropine eye drop studies for myopia control, along with information on trials currently underway.
This month’s science update on all things myopia includes a myopia management strategy from Dutch researchers using growth charts and 0.5% atropine; genetic research; and atropine 0.01% influence on accommodation and pupil size.
Welcome to Part 2 of the updates from the American Academy of Optometry 2019 Meeting. These updates all sprung from
